Compliance & Validation — Not documented by Atlas
Ask the vendor: Which compliance certifications (HIPAA, 21 CFR Part 11, SOC 2, GxP) do you hold?
Immunai
Immune-system mapping platform (AMICA) combining single-cell multiomics and ML for target and biomarker discovery.
Immunai, founded in 2018 and headquartered in New York, maps and models the immune system using single-cell multiomics and machine learning through its AMICA platform, positioning itself as an infrastructure provider for pharmaceutical research rather than a drug developer. The company has raised Series B funding and disclosed partnerships including work with AstraZeneca. Atlas found no vendor-held security certifications documented on its site.
- Headquarters
- New York, United States
- Founded
- 2018
- Deployment options
- cloud
- Website
- https://www.immunai.com
- https://www.linkedin.com/company/immunai
Categories
AI Use Cases
- Target Identification & Validation
Vendor Scorecard
50% — Partial coverage. Coverage score — how completely Atlas documents Immunai across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.
Deployment & Hosting — Documented
cloud
Pricing Transparency — Not documented by Atlas
Ask the vendor: What is your pricing model, and what drives total cost of ownership?
Implementation & Onboarding — Not documented by Atlas
Ask the vendor: What is a realistic implementation timeline, and what onboarding support is included?
Organization & Role Fit — Documented
Mid-Size Biotech, Large Pharma, Top 20 Pharma, Drug Discovery, R&D Leadership
Solution Scope — Documented
Biomarker Discovery, Target Identification
Company Viability — Partially documented
Series B, Founded 2018
Always ask the vendor
Not captured in Atlas data — confirm directly. Excluded from the score above.
Data Rights & IP
Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?
Model Credibility & Explainability
Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?
Questions to Ask This Vendor
- How are AMICA-derived targets and biomarkers validated for our therapeutic area?
- What single-cell and multiomic data assets underpin the platform?
- How is IP ownership handled in partnership programs?
- What security and data-governance documentation is available for collaborators?